ArticleCrohn's & colitis 3602021
Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients.
Article in Crohn's & colitis 360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Physical Activity Improves Quality of Life in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2026Pooled it
- Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis.Journal of comparative effectiveness research · 2025Pooled it
- Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program.Inflammatory bowel diseases · 2025Trial
- Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.Med (New York, N.Y.) · 2025Trial
- Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.Journal of Crohn's & colitis · 2023Trial
- Trial
- Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.Journal of gastroenterology and hepatology · 2026Article
- Quorum-Sensing Molecules Are Elevated in Long-Standing Ulcerative Colitis and Are Linked to the Development of Colitis-Associated Cancer.Gastroenterology · 2026Article
- Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older (≥65 years) and younger (<65 years) patients.Intestinal research · 2026Article
- Cytomegalovirus Infection Is Associated with Increased Disease Activity and Worse Long-Term Course in Ulcerative Colitis.International journal of medical sciences · 2026Article
- From tissue to blood: an integrated multi-omics signature identifies fibrogenesis and neutrophil activation as key drivers of ulcerative colitis severity.Frontiers in immunology · 2026Article
- Article
- Article
- A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced Ulcerative Colitis Patients.Biomedicines · 2025Article
- Elevated Serum Protease 3 Antineutrophil Cytoplasmic Antibody in Mesalazine-Intolerant Ulcerative Colitis: A Potential Diagnostic Biomarker.Journal of clinical medicine · 2025Article
- The role of neutrophils in the pathophysiology of inflammatory bowel diseases.Periodontology 2000 · 2025Review
- Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody.Intestinal research · 2025Article
- Post-marketing Surveillance of Tofacitinib in Patients With Ulcerative Colitis in Japan: A Post Hoc Analysis of Safety and Effectiveness by Prior Biologic Status.Crohn's & colitis 360 · 2025Article
- Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.Journal of gastroenterology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding ulcerative colitis disease activity assessed via the full, modified, or partial Mayo Score may help clinicians apply results from clinical trials to practice and facilitate interpretation of recent and older studies. Methods: Mayo Score variables were assessed in a cross-sectional study of 2608 ulcerative colitis patients. Results: Permutations of Mayo Scores were highly correlated, and models predicting the omitted variable from each permutation demonstrated significant agreement between predicted and observed values. Conclusions: Partial/modified Mayo Scores may be used to predict endoscopic and Physician's Global Assessment scores, and serve as proxies for the full Mayo Score in clinical practice/trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.